Amedisys, Inc. (NASDAQ:AMED) Shares Sold by Marshall Wace LLP

Marshall Wace LLP decreased its position in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 43.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 194,603 shares of the health services provider's stock after selling 147,343 shares during the quarter. Marshall Wace LLP owned 0.59% of Amedisys worth $17,668,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Blue Trust Inc. grew its position in Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after acquiring an additional 124 shares during the last quarter. HBW Advisory Services LLC purchased a new position in Amedisys in the 4th quarter worth about $38,000. Versant Capital Management Inc lifted its holdings in Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock valued at $41,000 after buying an additional 183 shares in the last quarter. Vestcor Inc purchased a new stake in Amedisys in the 4th quarter valued at about $73,000. Finally, Venturi Wealth Management LLC grew its stake in Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock worth $89,000 after acquiring an additional 779 shares in the last quarter. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on AMED shares. Stephens reaffirmed an "equal weight" rating and set a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday, April 16th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $100.75.

Amedisys Stock Up 0.7 %

Shares of Amedisys stock traded up $0.64 on Thursday, reaching $94.27. The stock had a trading volume of 511,602 shares, compared to its average volume of 405,077. The stock has a market capitalization of $3.09 billion, a P/E ratio of 37.41, a P/E/G ratio of 1.78 and a beta of 0.89. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average price of $92.14 and a 200 day moving average price of $91.84.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business had revenue of $594.78 million during the quarter, compared to analysts' expectations of $597.43 million. As a group, equities research analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.